|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-7-11
|
|
pubmed:abstractText |
This article summarizes data submitted to the United States Food and Drug Administration for marketing approval of zoledronic acid (Zol; Novartis Pharmaceuticals, East Hanover, NJ), a bisphosphonate drug for treating patients with bone metastases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:GobburuJogarao V SJV,
pubmed-author:HsiehYungY,
pubmed-author:IbrahimAmnaA,
pubmed-author:LeightonJohnJ,
pubmed-author:LiNingN,
pubmed-author:PazdurRichardR,
pubmed-author:RahmanAtiqurA,
pubmed-author:RamA BAB,
pubmed-author:ScherNancyN,
pubmed-author:SeoMM,
pubmed-author:SridharaRajeshwariR,
pubmed-author:VauseDebraD,
pubmed-author:WilliamsGrantG,
pubmed-author:WoodRebeccaR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2394-9
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12855610-Antineoplastic Agents,
pubmed-meshheading:12855610-Bone Neoplasms,
pubmed-meshheading:12855610-Breast Neoplasms,
pubmed-meshheading:12855610-Clinical Trials, Phase III as Topic,
pubmed-meshheading:12855610-Diphosphonates,
pubmed-meshheading:12855610-Dose-Response Relationship, Drug,
pubmed-meshheading:12855610-Female,
pubmed-meshheading:12855610-Humans,
pubmed-meshheading:12855610-Imidazoles,
pubmed-meshheading:12855610-Kidney,
pubmed-meshheading:12855610-Male,
pubmed-meshheading:12855610-Multiple Myeloma,
pubmed-meshheading:12855610-Neoplasm Metastasis,
pubmed-meshheading:12855610-Placebos,
pubmed-meshheading:12855610-Prostatic Neoplasms,
pubmed-meshheading:12855610-Time Factors,
pubmed-meshheading:12855610-United States,
pubmed-meshheading:12855610-United States Food and Drug Administration
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
|
|
pubmed:affiliation |
Division of Oncology Drug Products, Center for Drug Evaluation and Research, Rockville, Maryland 20857, USA. ibrahima@cder.fda.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
